INTRODUCTION {#s1}
============

Although the incidence of gastric cancer has decreased worldwide, it is still the fifth most common malignancy and the third leading cause of cancer-related mortality in the world \[[@R1]\]. Surgical resection with extended lymph node clearance remains the only curative therapy for non-metastatic gastric cancer. Even with advances in surgical techniques and adjuvant therapy, the prognosis of advanced gastric cancer is still discouraging due to late diagnosis \[[@R2]\].

A variety of factors are well recognized as prognostic indicators for gastric cancer, including tumor size, tumor depth, lymph node metastasis (LNM), and vessel involvement \[[@R3], [@R4]\]. In addition, elevated levels of preoperative tumor markers, including CEA \[[@R5]\], CA19-9 \[[@R6]\], AFP \[[@R7]\], and CA125 \[[@R8]\], were demonstrated to be associated with gastric cancer prognosis. However, the prognostic values of these tumor markers within the normal range have not yet been investigated. Therefore, the purpose of this study was to explore the prognostic values of normal, preoperative CEA, CA19-9, AFP, and CA125 levels in gastric cancer.

RESULTS {#s2}
=======

There were 1477 males (76.6%) and 450 females (23.4%) enrolled in this study. The patient age ranged from 20-86 years (median, 57; mean, 56.6). The follow-up time ranged from 1 to 75 months (median, 26.0; mean, 29.7). The 1-, 3- and 5-year overall survival (OS) rates were 93.7%, 75.6% and 68.0%, respectively (Figure [1](#F1){ref-type="fig"}). The optimal cut-off values of normal serum CEA, CA19-9, AFP, and CA125 for the prognosis of gastric cancer were calculated using X-tile software and are shown in Figures [2](#F2){ref-type="fig"}--[5](#F5){ref-type="fig"}. The optimal cut-off values were: 0.71 for CEA (P=0.317), 9.22 for CA19-9 (P=0.009), 3.76 for AFP (P=0.008), and 15.65 for CA125 (P=0.006).
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Thus, CA19-9, AFP, and CA125 were tested in univariate and multivariate analyses as prognostic predictors of gastric cancer. The univariate analysis showed that age, tumor size, pathological type, tumor depth, LNM, CA19-9, AFP, and CA125 were risk factors for gastric cancer (Table [1](#T1){ref-type="table"}). However, only age, tumor size, pathological type, tumor depth, LNM, CA19-9, and AFP were independent prognostic factors according to multivariate analysis (Table [2](#T2){ref-type="table"}). Moreover, relatively high levels of CA19-9, AFP, and CA125 were associated with poor prognosis (5-year OS: 70.6% vs 64.2%, P\<0.001. 69.6% vs 54.5%, P=0.011. 70.2% vs 54.9%, P\<0.001; Figures [6](#F6){ref-type="fig"}--[8](#F8){ref-type="fig"}). Clinicopathological features between the high- and low-level groups of CA19-9, AFP, and CA125 were analyzed and are summarized in Tables [3](#T3){ref-type="table"}--[5](#T5){ref-type="table"}, respectively. Serum CA19-9 levels were correlated with gender, age, and tumor depth (all P\<0.05), serum AFP levels were correlated with pathological type (P=0.005), and serum CA125 levels were correlated with gender, tumor size, pathological type, tumor depth, and LNM (all P\<0.05).

###### Univariate analysis of risk factors for prognosis of gastric cancer

  Prognostic factors      β        Hazard ratio (95% CI)   P value
  ----------------------- -------- ----------------------- ---------
  Gender                  0.226    1.253(0.999-1.572)      0.051
  Age                     0.234    1.264(1.035-1.542)      0.021
  Tumor location          −0.037   0.964(0.868-1.070)      0.488
  Tumor size              1.291    3.636(2.977-4.441)      0.000
  Pathological type       0.554    1.740(1.509-2.007)      0.000
  Tumor depth             0.872    2.393(2.124-2.696)      0.000
  Lymph node metastasis   0.777    2.174(1.986-2.380)      0.000
  CEA                     −0.213   0.808(0.606-1.077)      0.808
  CA19-9                  0.376    1.456(1.194-1.777)      0.000
  AFP                     0.348    1.417(1.083-1.852)      0.011
  CA125                   0.493    1.637(1.286-2.085)      0.000

###### Multivariate analysis of risk factors for prognosis of gastric cancer

  Prognostic factors      β       Hazard ratio (95% CI)   P value
  ----------------------- ------- ----------------------- ---------
  Age                     0.247   1.280(1.005-1.630)      0.046
  Tumor size              0.623   1.865(1.447-2.405)      0.000
  Pathological type       0.262   1.300(1.030-1.640)      0.027
  Tumor depth             0.436   1.547(1.293-1.850)      0.000
  Lymph node metastasis   0.520   1.683(1.472-1.923)      0.000
  CA19-9                  0.331   1.393(1.096-1.770)      0.007
  AFP                     0.459   1.583(1.166-2.149)      0.003
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###### Comparison of clinicopathological characteristics between two groups

  Characteristics                 Low CA19-9 (n=1134)   High CA19-9 (n=793)   P value
  ------------------------------- --------------------- --------------------- ---------
  Gender                                                                      0.013
   Male                           892                   585                   
   Female                         242                   208                   
  Age                                                                         0.000
   ≤60                            744                   425                   
   \>60                           390                   368                   
  Tumor location                                                              0.360
   Upper third                    290                   218                   
   Middle third                   218                   131                   
   Lower third                    538                   389                   
   Entire                         88                    55                    
  Tumor size (cm)                                                             0.369
   ≤5                             858                   614                   
   \>5                            276                   179                   
  Pathological type                                                           0.890
   Well differentiated            145                   100                   
   Moderately differentiated      276                   187                   
   Poorly differentiated          670                   480                   
   Signet ring cell or Mucinous   43                    26                    
  Tumor depth                                                                 0.004
   T1                             307                   201                   
   T2                             192                   134                   
   T3                             384                   228                   
   T4                             251                   230                   
  Lymph node metastasis                                                       0.052
   N0                             527                   319                   
   N1                             199                   148                   
   N2                             170                   134                   
   N3                             238                   192                   

###### Comparison of clinicopathological characteristics between two groups

  Characteristics                 Low AFP (n=1687)   High AFP (n=240)   P value
  ------------------------------- ------------------ ------------------ ---------
  Gender                                                                0.105
   Male                           1303               174                
   Female                         384                66                 
  Age                                                                   0.235
   ≤60                            1015               154                
   \>60                           672                86                 
  Tumor location                                                        0.746
   Upper third                    444                64                 
   Middle third                   300                49                 
   Lower third                    818                109                
   Entire                         125                18                 
  Tumor size (cm)                                                       0.304
   ≤5                             1295               177                
   \>5                            392                63                 
  Pathological type                                                     0.005
   Well differentiated            209                36                 
   Moderately differentiated      426                37                 
   Poorly differentiated          989                161                
   Signet ring cell or Mucinous   63                 6                  
  Tumor depth                                                           0.185
   T1                             439                69                 
   T2                             294                32                 
   T3                             542                70                 
   T4                             412                69                 
  Lymph node metastasis                                                 0.949
   N0                             744                102                
   N1                             302                45                 
   N2                             267                37                 
   N3                             374                56                 

###### Comparison of clinicopathological characteristics between two groups

  Characteristics                 Low CA125 (n=1608)   High CA125 (n=319)   P value
  ------------------------------- -------------------- -------------------- ---------
  Gender                                                                    0.000
   Male                           1268                 209                  
   Female                         340                  110                  
  Age                                                                       0.345
   ≤60                            983                  186                  
   \>60                           625                  133                  
  Tumor location                                                            0.334
   Upper third                    429                  79                   
   Middle third                   295                  54                   
   Lower third                    772                  155                  
   Entire                         112                  31                   
  Tumor size (cm)                                                           0.000
   ≤5                             1255                 217                  
   \>5                            353                  102                  
  Pathological type                                                         0.038
   Well differentiated            217                  28                   
   Moderately differentiated      392                  71                   
   Poorly differentiated          939                  211                  
   Signet ring cell or Mucinous   60                   9                    
  Tumor depth                                                               0.003
   T1                             436                  72                   
   T2                             287                  39                   
   T3                             504                  108                  
   T4                             381                  100                  
  Lymph node metastasis                                                     0.000
   N0                             739                  107                  
   N1                             286                  61                   
   N2                             252                  52                   
   N3                             331                  99                   

The prognostic value of the combination of CA19-9, AFP, and CA125 for gastric cancer was also evaluated. Gastric cancer patients were divided into four groups: Group 1) low CA19-9, low AFP and low CA125; Group 2) high CA19-9, low AFP, and low CA125; or low CA19-9, high AFP, and low CA125, or low CA19-9, low AFP, and high CA125; Group 3) high CA19-9, high AFP, and low CA125, or high CA19-9, low AFP, and high CA125; or low CA19-9, high AFP, and high CA125; and Group 4) high CA19-9, high AFP, and high CA125. As shown in Figure [9](#F9){ref-type="fig"}, OS rates were gradually reduced along with increasing levels of CA19-9, AFP, and CA125 (P\<0.001).

![Overall survival of gastric cancer patients according to the combination of CA19-9, AFP, and CA125 levels](oncotarget-07-58459-g009){#F9}

DISCUSSION {#s3}
==========

A large number of studies have investigated the predictive value of elevated preoperative serum CEA, CA19-9, AFP, and CA125 levels for the prognosis of gastric cancer. However, no studies have investigated the prognostic value of normal CEA, CA19-9, AFP, and CA125 levels in gastric cancer patients. The present study found that relatively high levels of CA19-9, AFP, and CA125 within the normal limits were associated with a poor prognosis in gastric cancer.

Elevated preoperative serum CEA, CA19-9, AFP, and CA125 have been previously associated with a poor prognosis in gastric cancer. A meta-analysis of 14,651 gastric cancer patients found that elevated serum CEA was an independent prognostic risk factor \[[@R5]\]. Similarly, another meta-analysis of 11,408 gastric cancer patients showed that elevated serum CA19-9 was associated with a poor prognosis \[[@R9]\]. Elevated serum AFP has also been associated with a poor prognosis in gastric cancer, and it can predict liver metastasis after radical resection \[[@R7], [@R10], [@R11]\]. Elevated serum CA125 levels have been associated with peritoneal metastasis of gastric cancer \[[@R12], [@R13]\], and elevated CA125 in peritoneal lavage was associated with peritoneal dissemination and a poor prognosis \[[@R14]\].

Although gastric cancer patients with normal, preoperative serum CEA, CA19-9, AFP, and CA125 had favorable prognoses, the prognostic value of relatively high levels of the four tumor markers within the normal limits was important to test. We found that relatively high levels of CA19-9, AFP, and CA125 were associated with poor prognosis of gastric cancer. However, serum CEA did not have prognostic value. Further, the combination of relatively high levels of CA19-9, AFP, and CA125 increased the prognostic value for gastric cancer, even though the levels were all within the normal limits. These results provide new insights into the prognosis of gastric cancer patients with normal, preoperative tumor markers.

Levels of CEA, CA19-9, AFP, and CA125 are also widely used to monitor recurrence or metastasis of gastric cancer after radical gastrectomy. Patients with normal postoperative CEA levels have a better prognosis \[[@R15]\]. Similarly, Kwon et al. reported that postoperative normalization of CA19-9 can be a surrogate for potentially curative surgical treatment and can be used as a prognostic factor for gastric cancer \[[@R16]\]. However, the predictive value of these tumor markers within normal limits after radical gastrectomy still needs further investigation.

A strong correlation between tumor marker levels and clinicopathological characteristics has been reported previously. Serum CEA levels were associated with tumor depth, LNM, TNM stage, and liver metastasis \[[@R17], [@R18]\]. Serum CA19-9 levels were also associated with tumor depth and LNM, as well as lymphatic-vascular invasion \[[@R19], [@R20]\]. Serum AFP levels were associated with LNM, vascular invasion, and liver metastasis \[[@R21]\], and serum CA125 was correlated with vascular invasion, LNM, and tumor stage \[[@R22]\]. We found that serum CA19-9 levels were correlated with gender, age, and tumor depth, serum AFP levels were correlated with pathological type, and serum CA125 levels were correlated with gender, tumor size, pathological type, tumor depth, and LNM.

There are several limitations to our study. First, it was a retrospective study of a single center\'s experience. Multi-center studies are needed to verify these findings. Second, the sample size was not large, especially for the patients with high levels of CA19-9, AFP, and CA125, which may result in bias during analysis. Third, the prognostic value of normal, CEA, CA19-9, AFP, and CA125 levels for gastric cancer patients after radical gastrectomy during follow-up were not investigated. Nonetheless, we conclude that relatively high levels of preoperative serum CA19-9, AFP, and CA125 within the normal limits are associated with poor prognosis of gastric cancer. Thus, the combination of CA19-9, AFP and CA125 levels could further increase the predictive value for the prognosis of gastric cancer.

MATERIALS AND METHODS {#s4}
=====================

This study was performed in the Xijing Hospital of Digestive Diseases affiliated with the Fourth Military Medical University. From September 2008 to March 2015, a total of 1927 gastric cancer patients were enrolled. The inclusion criteria were as follows: 1) no neoadjuvant chemotherapy, 2) radical D2 gastrectomy, 3) normal, preoperative serum CEA, CA19-9, AFP, and CA125 levels, and 4) with follow-up data. This study was approved by the Ethics Committee of Xijing Hospital, and written informed consent was obtained from all patients before surgery.

The four serum tumor markers were detected within 7 days before surgery. The cut-off values for serum CEA, CA19-9, AFP, and CA125 were 5 ng/ml, 27 U/ml, 8.1 ng/ml, 35 U/ml. Preoperative data including gender, age, tumor location, serum CEA, serum CA19-9, serum AFP and serum CA125 were recorded. All patients were treated with proximal, distal, or total gastrectomy with D2 lymphadenectomy. The surgical procedure was based on the recommendations of the Japanese Gastric Cancer Treatment Guidelines \[[@R23]\]. The depth of primary tumor and degree of lymph node involvement were defined according to the TNM classification. Tumor size, differentiation status, tumor depth, and LNM data were also collected during the pathological examination. The patients remained in follow-up until November, 2015 with enhanced chest and abdominal CT and gastroscopy every 3 months.

Data were processed using SPSS 22.0 for Windows (SPSS Inc., Chicago, IL, USA). The optimal cut-off values of serum CEA, CA19-9, AFP, and CA125 for prognosis of gastric cancer were calculated using X-tile software \[[@R24]\]. Discrete variables were analyzed using Chi-square or Fisher\'s exact tests. Significant risk factors identified by univariate analysis were further assessed by multivariate analysis using logistic regression. OS was analyzed by Kaplan-Meier method. A P value of 0.05 was considered statistically significant.
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